Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZymoGenetics’ Atacicept Will Enter Phase II/III For Lupus Nephritis In Q4

This article was originally published in The Pink Sheet Daily

Executive Summary

Company and partner Merck Serono also are working with FDA to finalize protocol for study in general systemic lupus erythematosus.

You may also be interested in...



HGS Follows Its Single-Cytokine BLISS In Lupus

Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.

HGS Follows Its Single-Cytokine BLISS In Lupus

Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.

Merck Serono Drops Diabetes Investment After Portfolio Review

German biopharma seeks licensing partners for diabetes treatments now in development while firm focuses R&D on cancer, other indications.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel